Of Mice and Men and Wildlings



Stephan P. Rosshart Academic clinician scientist and DFG Emmy Noether principal investigator Head of the translational microbiome research laboratory and the gnotobiotic mouse facility Medical Center – University of Freiburg, Germany Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases



Topics of this presentation





Mouse models in translational research: Two examples of success stories in which mouse models revolutionized medicine and the treatment of patients





However, never stop questioning your models!





Mouse models: lost in translation(al research). Beside these rare success stories, the overwhelming majority of data does not successfully translate from the mouse to humans!



M. G. von Herrath et al. Lost in translation: Barriers to implementing clinical immunotherapeutics for autoimmunity. J. Exp. Med., 2005. // M. Hay et al. Clinical development success rates for investigational drugs. Nat. Biotechnol., 2014. // J. Seok et al., Genomic responses in mouse models poorly mimic human inflammatory diseases. PNAS, 2013. // J. Mestas et al., Of mice and not men: Differences between mouse and human immunology. J. Immunol., 2004. // T. Shay et al., Conservation and divergence in the transcriptional programs of the human and mouse immune systems. PNAS, 2013. // W. Mak et al., Lost in translation: Animal models and clinical trials in cancer treatment. Am. J. Transl. Res., 2014. // K. J. Payne et al., Immune-cell lineage commitment: Translation from mice to humans. Immunity, 2007. AND 50 ON AND 50 FORTH...



Mouse models: lost in translation(al research). What is the reason for failure in translation, how can we create better translational research models?



M. G. von Herrath et al. Lost in translation: Barriers to implementing clinical immunotherapeutics for autoimmunity. J. Exp. Med., 2005. // M. Hay et al. Clinical development success rates for investigational drugs. Nat. Biotechnol., 2014. // J. Seok et al., Genomic responses in mouse models poorly mimic human inflammatory diseases. PNAS, 2013. // J. Mestas et al., Of mice and not men: Differences between mouse and human immunology. J. Immunol., 2004. // T. Shay et al., Conservation and divergence in the transcriptional programs of the human and mouse immune systems. PNAS, 2013. // W. Mak et al., Lost in translation: Animal models and clinical trials in cancer treatment. Am. J. Transl. Res., 2014. // K. J. Payne et al., Immune-cell lineage commitment: Translation from mice to humans. Immunity, 2007. AND 50 ON AND 50 FORTH...



All mammals are metagenomic organisms





All mammals are metagenomic organisms and the metagenome, the combination of the host genome and the microbiome, is the driver of the mammalian phenotype





Of mice and men, and naturally co-evolved microbiota





We are Born to be Wild – this is the common link among mammals

































Humans are not like lab mice, humans are pretty dirty, especially during the critical time when their microbiome and immune system evolves!





Conclusion: Restore the common link "Born to be Wild"

All mammals are "Born to be Wild", thus:

We could make the microbiome of lab mice wild and dirty again - like ours - by giving them the microbiome of actual wild mice,

this approach should mature their immune system, make them more like us humans and increase their translational research value!



We are not alone with our opinion!

L. K. Beura *et al.*, Normalizing the environment recapitulates adult human immune traits in laboratory mice. *Nature*, 2016.

- T. A. Reese *et al.*, Sequential infection with common pathogens promotes human-like immune gene expression and altered vaccine response. *Cell Host Microbe*, 2016.
- S. P. Rosshart *et al.*, Wild mouse gut microbiota promotes host fitness and improves disease resistance. *Cell*, 2017.

S. Abolins *et al.*, The comparative immunology of wild and laboratory mice, Mus musculus domesticus. *Nat Commun*, 2017.

J. M. Leung *et al.*, Rapid environmental effects on gut nematode susceptibility in rewilded mice. *PLoS Biol*, 2018.



Let us make lab mice, their immune system and microbiome wild (dirty) again



Rosshart et al., Cell, 2017. Rosshart et al., Science, 2019.



Could wildlings have prevented failed clinical trials?











The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE BRIEF REPORT

Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412

Ganesh Suntharalingam, F.R.C.A., Meghan R. Perry, M.R.C.P., Stephen Ward, F.R.C.A., Stephen J. Brett, M.D., Andrew Castello-Cortes, F.R.C.A., Michael D. Brunner, F.R.C.A., and Nicki Panoskaltsis, M.D., Ph.D.



Rosshart et al., Science, 2019.

















The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein

Charles J. Fisher, Jr., M.D., Jan M. Agosti, M.D., Steven M. Opal, M.D., Stephen F. Lowry, M.D., Robert A. Balk, M.D., Jerald C. Sadoff, M.D., Edward Abraham, M.D., Roland M.H. Schein, M.D., and Ernest Benjamin, M.D. for the Soluble TNF Receptor Sepsis Study Group*



Rosshart et al., Science, 2019.



000



00000

- Comment



ନ୍ଦ୍ରକଳ୍ପିତ

800

Rosshart et al., Science, 2019.

In preclinical trials, where rodent and non-human primate models failed to predict the human response to harmful drug treatments, wildlings accurately phenocopied human immune responses and could have prevented these tragically failed human trials





Natural microbiota-based models may enable the discovery of microbiota-related novel disease treatments that may be translatable into the human system





Rosshart et al., Cell, 2017.

Concluding remarks

Wildlings may enable the discovery of novel disease treatments that cannot be studied in conventional laboratory mice

Further, they may increase the safety and success rate of transitioning bench results to bedside practice

3R: Moreover, using such models may be the more ethical approach (non-human primates)



Reproducibility of data created with conventional lab mice

Irreproducible and confliciting data due to divergent microbiota among commercial vendors and research institutes

"Embrace the diversity and document everything"

or

"use standardized microbiota"



Reproducibility of data created with conventional lab mice



"Embrace the d



UNIVERSITATS

Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria

Ivaylo I, Ivanov, ^{1,10} Koji Atarashi,^{3,10} Nicolas Manel,^{1,11} Eoin L. Brodie,^{4,11} Tatsuichiro Shima,^{7,11} Ulas Karaoz,⁴ Dongguang Wei,⁸ Katherine C, Goldfarb,⁶ Clark A, Santee,⁴ Susan V, Lynch,⁶ Takeshi Tanoue,³ Akemi Imaoka,⁷ Kkuji tich,⁸ Kiyoshi Takeda,⁹ Yoshinot Umesak³ Kennya Honda,^{3,4} and Dan R, Litman^{1,2,4}

New York University School of Medicine, New York, NY 10016, USA

¹ How to its University School on Medicine, New York, NY 10016, USA ² Laboratory of Immune Regulation, Graduate School of Medicine, WPI Immunology Frontier Research Center, Osaka University ²-2 Yamada-oka, Suita, Osaka 565-0671, Japan

Center for Environmental Biotechnology, Earth Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA Carl Zeiss SMT, Inc., Nanotechnology Systems Division, One Corporation Way, Peabody, MA 01990, USA "Division of Gastroenterology, Department of Medicine, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 USA

General Iva, uon Yrakuit Central Institute for Microbiological Research, Yaho 1796, Kunitachi, Tokyo 186–8650, Japan "Department of Veterinary Public Health, University of Tokyo, Burkyo-ku, Tokyo 113-8657, Japan *Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, 4-1-8 Honcho Kawaguchi,

Saltama, 332-0012 Japan ¹⁰These authors contributed equally to this work

"These authors contributed equally to this work

* Inise autors contribute equary to this work *Correspondence: honda@ongene.med.csaka-u.ac.(p (K.H.), ittman@satum.med.nyu.edu (D.R.L) DOI 10.1016/i.cell.2009.033

SUMMARY

immune disease.

system and have been implicated in prevention of damage The gastrointestinal tract of mammals is inhabited by hundreds of distinct species of commensal micro- mucosal barrier and in influencing systemic autoimmune organisms that exist in a mutualistic relationship with the host. How commensal microbiota influence Rakof-Nahoum and Medzhitov, 2008, CD4* T cells acquire the host immune system is poorly understood. We distinct functional properties in response to signals conveyed ure sost immune system is poorly understood. We show here that colonization of the small intestine of like with a single commensal microbe, segmented filamentous bacterium (SFR), is sufficient to induce the appearance of COAT Theper oper Single Single Comparison and automatic single Comparison and microbe appearance of COAT Theper oper Single Single Comparison and microbe appearance of COAT Theper oper Single Single Comparison and microbe appearance of COAT Theper oper Single Single Comparison and microbe appearance of COAT Theper oper Single Single Comparison and microbe single Comparison and single Comparison and single Comparison and microbe single co the appearance of CD4* T helper cells that produce Murphy, 2000, whereas the induced regulatory T (Treg) cells IL-17 and IL-22 (Th17 cells) in the lamina propria. suppress excessive immune responses (Gavin and Rudensky SFB adhere tightly to the surface of epithelial cells 2003). Th17 cells secrete interleukin-17 (IL-17), IL-17F, and in the terminal ileum of mice with Th17 cells but are IL-22 and have significant roles in protecting the host from absent from mice that have few Th17 cells. Coloniza- bacterial and fungal infections, particularly at mucosal surfaces tion with SFB was correlated with increased expres- Th17 cells also have potent inflammatory potential, and thus are sion of genes associated with inflammation and key mediators of autoimmune disease (Aujla et al., 2007; Bettelli antimicrobial defenses and resulted in enhanced et al., 2007). Th17 and Treg cells are both dependent on trans antimicrobial detenses and resulted in enhanced resistance to the intestinal pathogen Circbacker index of the intestinal pathogen Circbacker advand by the expression of the Inage-specific transpectively (Torten) test and regulated pathway may provide new opportunities tester ROM; and Rogist respectively (Torten) test, 2003;

influence the development and balance of the host immune

Cell

Hori et al. 2003: Ivanov et al. 2006: Khattri et al. 2003: Mannar for enhancing mucosal immunity and treating auto-et al., 2006; Veldhoen et al., 2006). At appropriate concentration of TGF-β and IL-6, antigen-activated CD4* T cells upregulate PORγt and express Th17 cell cytokines (Zhou et al., 2008).

ent everything"

piota"

Thought experiment: Should we embrace diversity?

Figure 2B





Thought experiment: Should we embrace diversity?





Thought experiment: Should we embrace diversity? This approach does not solve the underlying problem of divergent microbiota and will fail due to the complexity of the system!





Thought experiment: Should we standardize?





Thought experiment: Should we standardize? Standardization does make sense. However, it will not work with conventional laboratory microbiota, they are not stable and not resilient!





Characteristics of microbiota for standardization? Can natural microbiota-based models help with this issue?

Complete characterization of the microbiome Stability of microbiota over time Resilience of microbiota against environmental challenges Favourable translational research value.



Wildling microbiota possess multigenerational stability and are their composition is fully characterized

 log_(ppm)
 Generation

 0 5 10 15 20
 Wilding F5







Rosshart et al., Science, 2019.

Wildlings carry typical naturally occurring "pathogens" of wild mice and this composition is fully characterized. However, wildlings are healthy animals, they show no signs of spontaneous disease, carry no human pathogens and are BSL-1.

Wildlings (n = 34) Wild (- 00		
Virueee	Wildlings (n = 24) Wild mice (n = 20) Percent positive mico*	
Adenovirus type 1 & 2 (MAV-1 & MAV2)	Percent po	o o
Ectromelia virus (Mousepox)	ō	ō
Hantaan (HTNV/HANT)	0	0
Lactate dehydrogenase-elevating virus (LDV/LDH)	0	0
Minute virus of mice (MVM)	0	0
Mouse coronavirus (MHV)	83	90
Mouse cytomegalovirus (MCMV)	50	85
MOUSE parvoviruses (MPV)	46	/5
MPV 1 MPV 2	42	20
MPV 5	- 0	20
Generic parvovirus NS-1 (NS-1)	0	0
Mouse pneumonitis virus (K)	ō	ō
Mouse rotavirus (MRV/EDIM/ROTA-A)	13	20
Murine norovirus (MNV)	67	50
Mouse theilovirus (TMEV/GDVII)	0	0
Mouse thymic virus (MTLV)	21	40
Pneumonia virus of mice (PVM)	0	0
Polyoma virus (POLY)	50	70
Prospect Hill virus (PHV)	0	0
Reovirus tupe 1, 2, 3, 4 (REU)	0	0
Seridal Virus (SEIND)	71	60
Encenhelitozoon cuniculi (ECUN)	0	0
Bacteria	Percent po	sitive mice*
Beta hemolytic Streptococcus Group A	0	0
Beta hemolytic Streptococcus Group B	ō	5
Beta hemolytic Streptococcus Group C	0	ō
Beta hemolytic Streptococcus Group G	0	0
Bordetella bronchiseptica	0	0
Campylobacter	0	0
Cilia-associated respiratory bacillus (CARB)	0	0
Citrobacter rodentium	0	0
Bordetella hinzii	0	0
Clostridium pilitorme	0	0
Corynebacterium bovis Convoltatium kutschori	0	0
Enconhalitazioan auniquii (ECUN)	0	0
Helicoharter species	100	100
Helicobacter bilis	0	0
Helicobacter ganmani	100	100
Helicobacter hepaticus	13	10
Helicobacter mastomyrinus	4	5
Helicobacter rodentium	0	0
Helicobacter typhlonius	100	100
Klebsiella oxytoca	0	5
Klebsiella pneumoniae	0	0
Mycoplasma pulmonis (MPUL)	0	0
Pasteurella pneumotropica (Heyl)	75	50
Pasteurella pneumotropica (Jawetz)	100	80
Pseudomonas aeruginosa	8	5
Salmonella Genus	0	0
Staphyrococcus aureus	0	U
Proteus mirabilis Stroptobacillus moniliformis	0	5
Streptobacillus nonlinorniae	0	0
Parasites/Protozoa/Fungi	Percent no	sitive mice*
Pneumocvstis	0	0
Crytosporidium	0	0
Demodex	63	70
Entamoeba	33	10
Giardia	29	20
Spironucleus muris	83	65
Tritrichomonas	67	70
Mite species	100	100
Myobia musculi	100	95
Myocoptes musculinus	96	100
Radfordia affinis	83	90
Radfordia ensifera	0	0
Pinworm species	96	85
Aspiculuris tetraptera	58	25
sypnacia muris	0	5
	A.1	

[•] The pathogen profile was determined with the PRIA^{1M} (PCR Rodent Infectious Agent) Panel Surveillance Plus and the Scology Profile Assessment Plus by Charles River infectious agent testing (Charles River Laboratories). A mouse was considered pathogen-exposed if it tested positive in at least one of these independent assays.

Rosshart et al., Science, 2019.

Can natural microbiota-based models help with irreproducibility of biomedical data? Natural microbiota evolved under evolutionary pressure in the natural world. Thus, they may be stable and resilient and may therefore make a standardization possible!





Microbial challenge through co-housing





Rosshart et al., Science, 2019.

Antibiotic challenge with amoxicillin / clavulanate





Rosshart et al., Science, 2019.

Dietary challenge with high-fat diet





Rosshart et al., Science, 2019.

Concluding remarks I

The microbiota composition of the wildling model is fully characterized: "We do know exactly what we are dealing with"

Wild mouse microbiota possess multigenerational stability in lab mice under conventional SPF conditions, wildlings have no "special needs" as regards to housing and they are perfectly healthy (BSL-1)

Wild mouse microbiota possess extraordinary resilience against various environmental challenges and could be utilized in a feasible fashion

Indispensable characteristics for highly-controlled, long-term work and reproducible experimentation

Increased translational research value, a better model for human diseases



Concluding remarks II

Thus, natural gut microbiota have characteristics that are important for standardization and that would make it possible, if you want to standardize. Moreover, this standard would increase the translational research value of the model system, a better model for human diseases

Natural microbiota- and pathogen-based models may help to discover novel disease treatments that cannot be studied in conventional Laboratory mice

And all of this together may be the more ethical approach, may enhance the reproducibility of biomedical studies and increase the safety and success of translating immunological results from animal models to humans alongside a reduction in costs



What are the next steps?

"If you wish to be out front, act as if you were behind"

- Lao Tzu, ancient chinese poet and philosopher -

B Our mouse model from 2017 is already commercially available through Taconic Biosciences and we continue to optimize our models, e.g. we work on a goldstandard microbiome with potential commercial applications

* We use these novel mouse models in basic and preclinical research studies to:

I) discover novel treatments for a wide range of human diseases of global relevance including transplant rejection, GvHD, cancer, infectious diseases, allergies, autoimmune and inflammatory diseases, neurological disorders as well as cardiovascular diseases

II) support drug development in collaboration with the pharmaceutical industry

* We are aiming to establish new clinical microbiome studies and a SFB/TRR initiative

